



Supplementary Figure 1. Oncogenic Kras activation suppresses mitochondrial mass independently of Nrf2.

A) Median fluorescence intensity for LSL-KrasG12D; Nrf2^{-/-} (WT) MEFs compared to KrasG12D; Nrf2^{-/-} (G12D) MEFs stained with DCF-DA (Cyto ROS), MitoTracker Green (mitochondrial mass), DiIC15 (membrane potential) and MitoSox Red (mitochondrial ROS). Two-way ANOVA with Holm-Sidak test. B) Representative TEM micrographs of LSL-KrasG12D organoids infected with Adeno-Empty (WT) or Adeno-Cre (G12D). Scale bars: 500 nm. Black arrow: mitochondria; White arrowhead: autophagosomes. C) Quantification of mitochondrial volume fraction from TEM micrographs in C, Two-tailed t-test. D) mtDNA/nDNA ratio determined by qPCR for LSL-KrasG12D MEFs infected with Adeno-Empty (WT) or Adeno-Cre (G12D), n=5 independent experiments. Two-tailed t-test with Welch's correction. E) Schematic of FRT-LSL-KrasG12V-FRT allele. F) Representative image of 1LoxP PCR products from FRT-LSL-KrasG12V-FRT (FPC) tumor organoids treated with vehicle (Veh) or 4-OH-tamoxifen (Tam).